Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QRxPharma Pty Ltd.

This article was originally published in Start Up

Executive Summary

QRx's lead (Phase II) candidate is a morphine/oxycodone combination that takes advantage of the synergistic effect of those two opioids when combined to produce a more potent painkiller, with fewer side effects, than morphine administered alone. The company is also developing an extended-release version of the drug and has a platform for discovering venom-based therapeutics.

You may also be interested in...



Pain Therapeutics: A Market Rich in Unmet Medical Need and Competition

Start-ups venturing into the pain management arena will find them selves in a therapeutic category rich in both unmet medical need and competition. To compete, a number of newer companies are pursuing business models that balance the risks inherent in developing novel painkillers with more reliable, predictable routes to commercialization--such as creating next-generation versions of off-patent drugs and inlicensed technology, as well as establishing IP around already-elucidated targets.

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel